Literature DB >> 11382746

Real-time monitoring of the interactions of transforming growth factor-beta (TGF-beta ) isoforms with latency-associated protein and the ectodomains of the TGF-beta type II and III receptors reveals different kinetic models and stoichiometries of binding.

G De Crescenzo1, S Grothe, J Zwaagstra, M Tsang, M D O'Connor-McCourt.   

Abstract

Mature transforming growth factor-beta (TGF-beta) is proteolytically derived from the C terminus of a precursor protein. Latency-associated protein (LAP), the N-terminal remnant of the TGF-beta precursor, is able to bind and neutralize TGF-beta. Mature TGF-beta exerts its activity by binding and complexing members of two subfamilies of receptors, the type I and II receptors. In addition to these signaling receptors, TGF-beta can also interact with an accessory receptor termed the type III receptor. Using a surface plasmon resonance-based biosensor (BIAcore), we determined the mechanisms of interaction of four binding proteins (LAP, the type II and III receptor ectodomains (EDs), and a type II receptor ED/Fc chimera) with three TGF-beta isoforms, and we quantified their related kinetic parameters. Using global fitting based on a numerical integration data analysis method, we demonstrated that LAP and the type II receptor/Fc chimera interacted with the TGF-beta isoforms with a 1:1 stoichiometry. In contrast, the type II ED interactions with TGF-beta were best fit by a kinetic model assuming the presence of two independent binding sites on the ligand molecule. We also showed that the type III ED bound two TGF-beta molecules. Further experiments revealed that LAP was able to block the interactions of TGF-beta with the two EDs, but that the two EDs did not compete or cooperate with each other. Together, these results strongly support the existence of a cell-surface complex consisting of one type III receptor, two TGF-beta molecules, and four type II receptors, prior to the recruitment of the type I receptor for signal transduction. Additionally, our results indicate that the apparent dissociation rate constants are more predictive of the neutralizing potency of these TGF-beta-binding proteins (LAP, the type II and III receptor EDs, and the type II receptor/Fc chimera) than the apparent equilibrium constants.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11382746     DOI: 10.1074/jbc.M009765200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  25 in total

1.  Processing of anti-mullerian hormone regulates receptor activation by a mechanism distinct from TGF-beta.

Authors:  Nathalie di Clemente; Soazik P Jamin; Alexey Lugovskoy; Paul Carmillo; Christian Ehrenfels; Jean-Yves Picard; Adrian Whitty; Nathalie Josso; R Blake Pepinsky; Richard L Cate
Journal:  Mol Endocrinol       Date:  2010-09-22

2.  Peptide ligands that use a novel binding site to target both TGF-β receptors.

Authors:  Lingyin Li; Brendan P Orner; Tao Huang; Andrew P Hinck; Laura L Kiessling
Journal:  Mol Biosyst       Date:  2010-10-04

3.  Deletion of the proline-rich region of TonB disrupts formation of a 2:1 complex with FhuA, an outer membrane receptor of Escherichia coli.

Authors:  Cezar M Khursigara; Gregory De Crescenzo; Peter D Pawelek; James W Coulton
Journal:  Protein Sci       Date:  2005-03-31       Impact factor: 6.725

4.  Spatial control of cell fate using synthetic surfaces to potentiate TGF-beta signaling.

Authors:  Lingyin Li; Joseph R Klim; Ratmir Derda; Adam H Courtney; Laura L Kiessling
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-30       Impact factor: 11.205

Review 5.  Extracellular movement of signaling molecules.

Authors:  Patrick Müller; Alexander F Schier
Journal:  Dev Cell       Date:  2011-07-19       Impact factor: 12.270

6.  Epigallocatechin-3-gallate potently inhibits the in vitro activity of hydroxy-3-methyl-glutaryl-CoA reductase.

Authors:  Massimiliano Cuccioloni; Matteo Mozzicafreddo; Michele Spina; Chi Nhan Tran; Maurizio Falconi; Anna Maria Eleuteri; Mauro Angeletti
Journal:  J Lipid Res       Date:  2011-02-25       Impact factor: 5.922

7.  A new model for growth factor activation: type II receptors compete with the prodomain for BMP-7.

Authors:  Gerhard Sengle; Robert N Ono; Karen M Lyons; Hans Peter Bächinger; Lynn Y Sakai
Journal:  J Mol Biol       Date:  2008-07-02       Impact factor: 5.469

8.  The role of shear-induced transforming growth factor-β signaling in the endothelium.

Authors:  Tony E Walshe; Nathaniel G dela Paz; Patricia A D'Amore
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-08-22       Impact factor: 8.311

9.  Targeting of bone morphogenetic protein growth factor complexes to fibrillin.

Authors:  Gerhard Sengle; Noe L Charbonneau; Robert N Ono; Takako Sasaki; Jennifer Alvarez; Douglas R Keene; Hans Peter Bächinger; Lynn Y Sakai
Journal:  J Biol Chem       Date:  2008-03-13       Impact factor: 5.157

10.  Expression, purification and characterization of BG(E)RII: a novel pan-TGFbeta inhibitor.

Authors:  Erik V Verona; Yuping Tang; Thomas K Millstead; Andrew P Hinck; Joseph K Agyin; Lu-Zhe Sun
Journal:  Protein Eng Des Sel       Date:  2008-05-21       Impact factor: 1.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.